An Editorial Board of Your Peers
In keeping with our goal of reporting on the practical aspects of oncology, in this issue we highlight the new National Comprehensive Cancer Network%u2019s (NCCN) updated clinical practice guidelines for kidney and cervical cancers.
Oncology & Biotech News
Publications rely on their Editorial Boards to guide content and offer professional insight. As we continue to build the Editorial Board of , we’re looking for members who’ll assist in providing community-based oncologists and hematologists with practical resources each month. In fact, most of our current Board members (listed to the left) are community-based oncologists and hematologists. Their real world experience will shape our publication and provide you with solutions to the issues you face every day.
In keeping with our goal of reporting on the practical aspects of oncology, in this issue we highlight the new National Comprehensive Cancer Network’s (NCCN) updated clinical practice guidelines for kidney and cervical cancers. The NCCN guidelines are widely recognized and applied as the standard of care in both the community and academic practice settings. They are developed and updated via an evidence-based process with explicit review of the scientific evidence by a panel of experts physicians. At the end of the article, we guide you to the NCCN website, where you can obtain the guidelines free of charge.
This month’s Reimbursement and Managed Care department includes a summary of drugs cited in Beer’s Criteria, which specifies medicines that should be avoided or monitored with caution when used in the elderly. As the article mentions, inappropriate prescribing to this population is common in the last year of a patient’s life, especially among those with cancer.
Physicians’ Financial News
The department provides a financial view of our industry and the companies in it. Although some of us may not be interested in the financial aspects of the biotech and pharmaceutical companies that produce the products we use, Wall Street certainly is. At most clinical conferences, you can see financial analysts in attendance, monitoring the latest advances and combination therapies we prescribe. This department should shed some light on what others see when they look at our industry.
As always, your input is valued. Contact us with any thoughts, comments, and ideas regarding our publication.
